Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimers disease (AD) unfolds over decades preceding cognitive symptoms, and measuring the full scope of its molecular complexity remains difficult. Blood-based biomarkers of amyloid, phosphorylated tau, astrocytic reactivity and neuroaxonal injury--including A{beta}42/40, p-tau181, p-tau217, GFAP and NfL--enable scalable assessment of AD-related pathology and associated processes but capture only a narrow slice of the systemic biology ultimately shaping disease progression. Here we link these increasingly routine clinical assays to the plasma proteome using multi-omic linear modeling to resolve functional heterogeneity in AD progression. In 484 older adults spanning normal cognition, mild cognitive impairment (MCI) and AD, we derived proteomic signatures for each key biomarker across more than 6,000 proteins, uncovering overlapping and distinct biological processes and cell types implicated in AD with robust signal across proteomic modalities. From these we built continuous progression-focused functional modules that were consistently preserved across 12 independent cohorts comprising 11,042 participants from the Global Neurodegeneration Proteomics Consortium and that associated with cognitive decline, diagnosis and AD-relevant biology. A synaptic vesicle module marked apparent neuronal resilience as much as 5 years before estimated symptom onset. We show routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.

What this study adds

Evidence grade: Low

The record lists 11,042 participants. By linking routine Alzheimer's blood biomarkers to thousands of plasma proteins, the researchers built progression-related modules that held up across 12 independent cohorts and were tied to cognitive decline. One synaptic module marked apparent neuronal resilience up to five years before estimated symptom onset.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Butler, R. R., Brown, M. P., Weber, A., Cary, G. A., Le Guen, Y., Moran Losada, P., et al. (2026). Alzheimers disease blood biomarkers reveal proteomic modules of disease progression. medRxiv (preprint). https://doi.org/10.64898/2026.08.14.26360394

Vancouver

Butler RR, Brown MP, Weber A, Cary GA, Le Guen Y, Moran Losada P, et al. Alzheimers disease blood biomarkers reveal proteomic modules of disease progression. medRxiv (preprint). 2026. doi:10.64898/2026.08.14.26360394.

BibTeX

@article{butler2026-ab713afc,
  author  = {Butler, R. R. and Brown, M. P. and Weber, A. and Cary, G. A. and Le Guen, Y. and Moran Losada, P. and Mendiola, J. H. and Henderson and others},
  title   = {{Alzheimers disease blood biomarkers reveal proteomic modules of disease progression}},
  journal = {medRxiv (preprint)},
  year    = {2026},
  doi     = {10.64898/2026.08.14.26360394},
  url     = {https://doi.org/10.64898/2026.08.14.26360394}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

By linking routine Alzheimer's blood biomarkers to thousands of plasma proteins, the researchers built progression-related modules that held up across 12 independent cohorts and were tied to cognitive decline. One synaptic module marked apparent neuronal resilience up to five years before estimated symptom onset.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 4 of 10; How recent 5 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 0 of 4; Institution's track record 3 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 26 of the 94 points it could be judged on, which is 28 of 100. Raw total 28 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 28 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 28 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 26 of the 94 points we could judge it on, which is 28 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv (preprint))
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 4 / 4 11,042 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 0 / 4 Last-listed author Edward N. Wilson: h-index 2 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 26 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 94 points we could judge it on is 28 out of 100.
Total 28 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Related studies in Biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →